Two In a Row From Science: Car-T Cells Are Back With a New Upgrade That May Eradicate Deadly Solid Tumours!
Science has published two consecutive research articles that suggest new ways to improve the efficacy of CAR-T for solid tumours.
Science has published two consecutive research articles that suggest new ways to improve the efficacy of CAR-T for solid tumours.
The US FDA has approved pemigatinib, the first targeted drug to date for patients with specific mutated blood tumours, and the results of the study show that the drug made tumours disappear completely in 79% of patients!
A new study shows that for a common type of skin cancer, squamous cell carcinoma of the skin, immunotherapy before surgery resulted in the complete disappearance of tumours in 50.6% of patients and more than 90% in 12.7% of patients.
A three-drug combination regimen significantly prolongs survival in patients with HPV-positive cancers, new data from a clinical trial shows. For patients who had not been treated with immune checkpoint inhibitors, it resulted in significant tumour shrinkage in 88% of patients, and even in patients who failed immune checkpoint inhibitor treatment, 63% had significant tumour shrinkage.